What are the most effective treatments for psoriasis? How do current and pipeline therapies compare in terms of efficacy, safety, and cost-effectiveness? Leading KOLs evaluate Bimzelx (bimekizumab) as the most prescribed anti-IL17 due to its high efficacy and manageable side effects. Skyrizi (risankizumab) is identified as the leader in the anti-IL23 category, with Tremfya (guselkumab) also gaining traction for its cost-effectiveness. Johnson & Johnson's oral drug JNJ 77242113 shows significant potential to compete with existing treatments like Otezla (apremilast) and Sotyktu (deucravacitinib). Gain valuable insights into the current and future treatment paradigms for psoriasis, informed by expert opinions and detailed analysis.
Key brands covered in this report:
Humira
Enbrel
Remicade
Cimzia
Cosentyx
Taltz
Siliq/Kyntheum
Stelara
Tremfya
Ilumya/Ilumetri
Skyrizi
Otezla
Bimzelx
Sotyktu
piclidenoson
zasocitinib
JNJ 77242113
Key questions answered:
How are current therapies for psoriasis used and perceived in terms of efficacy, tolerability, and ease of administration? How do they compare with pipeline options?
Which drug class (anti-TNFs, anti-IL-12/23s, anti-IL-23s, anti-IL-17s and oral therapies) has the greatest potential to impact prescribing trends?
How will the launch of biosimilars and the use of current, as well as newly approved/pipeline drugs, impact the psoriasis treatment paradigm in terms of patient segment, line of therapy, and preference?
Are there any promising pipeline products and if so, how will they impact the current players in the market?
Which clinical trials have the potential to impact prescribing trends, and how will the results affect the future treatment of psoriasis?
How will the treatment landscape for psoriasis evolve in the future for each patient segment and line of therapy?
What are KOLs' demands and expectations from the psoriasis market?
Table of Contents
Executive Summary
Research Objectives
Anti-TNF drugs
Humira (adalimumab; AbbVie), Remicade (infliximab; Merck & Co./Johnson & Johnson Innovative Medicine), Enbrel (etanercept; Amgen), Cimzia (certolizumab; UCB)
Key insights summary
Anti-IL17 drugs
Cosentyx (secukinumab; Novartis)
Key insights summary
Taltz (ixekizumab; Lilly)
Key insights summary
Siliq (US)/Kyntheum (EU)brodalumab; Ortho Dermatologics/LEO Pharma)
Key insights summary
Bimzelx (bimekizumab; UCB)
Key insights summary
Anti-IL12/23 drugs
Stelara (ustekinumab; Johnson & Johnson Innovative Medicine)
Key insights summary
Anti-IL23 drugs
Tremfya (guselkumab; Johnson & Johnson Innovative Medicine)
Key insights summary
Ilumya/Ilumetri (tildrakizumab; Sun Pharma/Almirall)
Key insights summary
Skyrizi (risankizumab; AbbVie)
Key insights summary
PDE IV antagonists
Otezla (apremilast; Amgen)
Key insights summary
Tyrosine Kinase 2 inhibitor
Sotyktu (deucravacitinib; Bristol Myers Squibb)
Key insights summary
Pipeline drugs
Piclidenoson (Can-Fite BioPharma)
Key insights summary
Zasocitinib (TAK 279; Takeda)
Key insights summary
JNJ 77242113 (Johnson & Johnson Innovative Medicine)
Key insights summary
Future outlook and treatment dynamics for management of psoriasis
Key insights summary
Risankizumab, guselkumab and bimekizumab will pose strong competition to other drugs within the psoriasis treatment paradigm: biosimilars will enable early intervention with biologics
Appendix
KOL Bulletins